You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 21, 2024

Erythromycin ethylsuccinate - Generic Drug Details


✉ Email this page to a colleague

« Back to Dashboard


What are the generic sources for erythromycin ethylsuccinate and what is the scope of freedom to operate?

Erythromycin ethylsuccinate is the generic ingredient in twelve branded drugs marketed by Azurity, Amneal Pharms, Ani Pharms, Cadila Pharms Ltd, Endo Operations, Ross Labs, Pharmacia And Upjohn, Arbor Pharms Llc, Alpharma Us Pharms, Dista, Naska, Parke Davis, Pharmafair, Wyeth Ayerst, Aurobindo Pharma Usa, Barr, and Alra, and is included in twenty-five NDAs. Additional information is available in the individual branded drug profile pages.

There are fourteen drug master file entries for erythromycin ethylsuccinate. Eight suppliers are listed for this compound.

Summary for erythromycin ethylsuccinate
US Patents:0
Tradenames:12
Applicants:17
NDAs:25
Drug Master File Entries: 14
Finished Product Suppliers / Packagers: 8
Raw Ingredient (Bulk) Api Vendors: 48
Clinical Trials: 1
Patent Applications: 8,715
What excipients (inactive ingredients) are in erythromycin ethylsuccinate?erythromycin ethylsuccinate excipients list
DailyMed Link:erythromycin ethylsuccinate at DailyMed
Recent Clinical Trials for erythromycin ethylsuccinate

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University of FloridaPhase 2
Metabolic Solutions Inc.Phase 2

See all erythromycin ethylsuccinate clinical trials

Pharmacology for erythromycin ethylsuccinate
Medical Subject Heading (MeSH) Categories for erythromycin ethylsuccinate

US Patents and Regulatory Information for erythromycin ethylsuccinate

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Cadila Pharms Ltd ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 216212-002 Nov 21, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ross Labs PEDIAZOLE erythromycin ethylsuccinate; sulfisoxazole acetyl GRANULE;ORAL 050529-001 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Cadila Pharms Ltd ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 216212-001 Nov 21, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Ani Pharms ERYTHROMYCIN ETHYLSUCCINATE erythromycin ethylsuccinate GRANULE;ORAL 062055-001 Approved Prior to Jan 1, 1982 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.